Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 6.7%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was down 6.7% on Tuesday . The stock traded as low as $5.42 and last traded at $5.54, approximately 819,760 shares were traded during trading. An increase of 18% from the average daily volume of 691,826 shares. The stock had previously closed at $5.94.

Several analysts have recently weighed in on LXRX shares. ValuEngine lowered shares of Wolverine World Wide from a “hold” rating to a “sell” rating in a report on Monday, May 20th. Wedbush set a $175.00 price objective on shares of Lululemon Athletica and gave the stock a “hold” rating in a report on Tuesday, June 11th. BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, June 27th. Needham & Company LLC raised their price objective on shares of Alteryx to $108.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, Gabelli raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 25th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. Lexicon Pharmaceuticals has an average rating of “Hold” and an average target price of $16.38.

The company has a market capitalization of $631.24 million, a price-to-earnings ratio of -4.86 and a beta of 0.84. The firm’s fifty day moving average is $5.92.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $9.20 million during the quarter, compared to analyst estimates of $13.26 million. The business’s revenue for the quarter was down 63.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.40) EPS. On average, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.47 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Paloma Partners Management Co acquired a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at approximately $73,000. First Manhattan Co. acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter valued at approximately $15,282,000. Clearbridge Investments LLC increased its holdings in shares of Lexicon Pharmaceuticals by 3.4% in the first quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock valued at $7,184,000 after purchasing an additional 42,540 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Lexicon Pharmaceuticals by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock valued at $3,752,000 after purchasing an additional 13,664 shares in the last quarter. Finally, Gamco Investors INC. ET AL increased its holdings in shares of Lexicon Pharmaceuticals by 10.0% in the first quarter. Gamco Investors INC. ET AL now owns 22,000 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 2,000 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: What causes a recession?

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit